About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Creatine Supplementation During Resistance Training for People Recovering From Stroke

Clinicaltrials.gov identifier NCT03941678

Recruitment Status Completed

First Posted May 8, 2019

Last update posted June 11, 2020

Study Description

Brief summary:

Creatine monohydrate is important for sustaining phosphocreatine stores in tissues such as muscle and brain. Phosphocreatine is an important source of energy in these tissues. Supplementation with creatine monohydrate is effective in healthy and clinical populations for improving muscle and brain function. The purpose of our study is to determined whether creatine supplementation is effective during resistance training for improving muscle and brain function in people recovering from stroke.

  • Condition or Disease:Stroke
  • Intervention/Treatment: Dietary Supplement: Creatine monohydrate
    Dietary Supplement: Placebo
  • Phase: N/A
Detailed Description

The purpose of this study is to determine the effects of creatine supplementation and supervised resistance training in stroke survivors. It is hypothesized that creatine supplementation and resistance training will increase whole-body lean tissue mass, limb muscle thickness, muscle strength, tasks of functionality and cognition and decrease symptoms of depression and anxiety compared to placebo and resistance training. Stroke is characterized by an abrupt disturbance in cerebral circulation causing a neurological deficit. It is a major cause of adult neurological disability in North America, often resulting in significant muscle loss, weakness and functional limitations. Disability associated with stroke limits independent living and social participation in at least half of all stroke survivors. A sedentary lifestyle after stroke can increase the risk for recurrent stroke, cardiovascular disease, and diabetes mellitus. All factors may adversely affect independence and quality of life. The majority of stroke survivors have residual impairments such as hemiparesis, spasticity, cognitive dysfunction, and aphasia, with full recovery reached in a small portion of these individuals. One of the major consequences of these impairments is physical inactivity which inevitably contributes to muscle loss, decreased muscle function (i.e. strength, endurance) and impaired functionality. One intervention which may help improve muscle mass, muscle function and functionality in stroke survivors is supervised resistance training. Resistance training does not lead to muscle spasticity in stroke survivors and has been shown to improve the ability to perform activities of daily living. Another intervention which may be beneficial for stroke survivors is creatine supplementation. Creatine has been shown to increase muscle mass, muscle function and tasks of functionality when combined with resistance training, possibly by influencing cellular hydration status, high-energy phosphate metabolism, muscle protein kinetics, satellite cells, anabolic growth factors, and inflammation. Creatine has also shown promise for improving cognition and symptoms of depression and anxiety; however, no study has examined the combined effects of creatine supplementation and resistance training in stroke survivors. The study will be a double-blind, repeated measures design. In order to minimize group differences, participants will be matched according to age, gender, and type of stroke and then be randomized on a 1:1 basis to one of two groups, creatine monohydrate or placebo (corn-starch maltodextrin). Creatine and placebo will be similar in taste, color, texture and appearance. A research assistant will be responsible for randomization and another research assistant will prepare study kits. Each study kit will contain the participants supplement for the duration of the study, detailed supplementation instructions, as well as measuring spoons. For days 1-7, participants will ingest 0.3g/kg of creatine or placebo (0.075 g/kg x 4 times daily). This creatine dosing strategy has been shown to be effective for increasing intramuscular creatine stores. For subsequent days, participants will consume 0.1 g/kg/day of creatine or placebo as this creatine dosage is effective for increasing muscle mass. On training days, participants will consume their supplement within 5 minutes after each training session. On non-training days, supplements will be consumed at the participants leisure. Adherence with creatine supplementation, placebo, and resistance training will be assessed by training and supplementation compliance logs. A retrospective treatment identification will be administered to all participants upon completion of the study in order to assess whether participants thought they were administered creatine, placebo, or unsure about what supplement they consumed. The dependent variables that will be measured at baseline and after the intervention include: (1) whole-body lean tissue mass (dual energy x-ray absorptiometry) (2) muscle thickness (elbow and knee flexors and extensors; ultrasonography), (3) muscle strength (1-repetition maximum leg press and chest press), (4) tasks of functionality (berg balance scale, 6-minute walk test) (5) cognition (Montreal Cognitive Assessment), (6) depression (The Center for Epidemiologic Studies- Depression Scale) and anxiety (Generalized Anxiety Disorder 7-item). Participants will also complete a 3-day food log at baseline and during the last week of supplementation and training to determine whether total calories consumed as well as macronutrient intake changed over the duration of the study. Participants will be instructed to record all food and beverages consumption during these 3 days. Food records will be analyzed using MyFitnessPal.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 8 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Parallel groups: creatine and placebo
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: The Effect of Creatine Supplementation and Resistance Training in Stroke Survivors
  • Actual Study Start Date: May 2019
  • Actual Primary Completion Date: December 2019
  • Actual Study Completion Date: May 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Creatine
0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
Dietary Supplement: Creatine monohydrate
0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
Placebo Comparator: Placebo
0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
Dietary Supplement: Placebo
0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
Outcome Measures
  • Primary Outcome Measures: 1. Walking ability [ Time Frame: Change from baseline to 10 weeks ]
    6-minute walk test (maximal distance)
  • Secondary Outcome Measures: 1. Lean tissue mass [ Time Frame: Change from baseline to 10 weeks ]
    Lean tissue mass determined by DXA
  • 2. Leg muscle thickness [ Time Frame: Change from baseline to 10 weeks ]
    Knee extensor muscle thickness by ultrasound
  • 3. Arm muscle thickness [ Time Frame: Change from baseline to 10 weeks ]
    Biceps muscle thickness by ultrasound
  • 4. Leg strength [ Time Frame: Change from baseline to 10 weeks ]
    Leg press 1-repetition maximum
  • 5. Upper body strength [ Time Frame: Change from baseline to 10 weeks ]
    Chest press 1-repetition maximum
  • 6. Balance [ Time Frame: Change from baseline to 10 weeks ]
    Berg balance scale to measure balance. Includes 14 sub-scales which are summed. Scoring range is from 0 (worse) to 56 (best)
  • 7. Cognition [ Time Frame: Change from baseline to 10 weeks ]
    Montreal cognitive assessment to assess cognitive ability. Seven sub-scales which are summed. Scoring range is from 0 (worse) to 30 (best)
  • 8. Anxiety [ Time Frame: Change from baseline to 10 weeks ]
    General Anxiety Disorder Assessment to assess anxiety. Seven questions whose scores are summed. Scoring range is from 0 (least anxious) to 21 (most anxious)
  • 9. Depression [ Time Frame: Change from baseline to 10 weeks ]
    Center for Epidemiologic Depression (CES-D) Scale to assess depression. Twenty questions whose scores are summed. Scoring range is from 0 (least depressed) to 60 (most depressed)
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

- At least 6 months post-stroke

Exclusion Criteria:

- creatine supplementation within the past 12 weeks

- medications affecting muscle function within the past 12 weeks

- kidney disorders

- liver disorders

Contacts and Locations
Contacts
Locations

Canada, Saskatchewan
Faculty of Kinesiology and Health Sciences, University of Regina
Regina

Canada, Saskatchewan
College of Kinesiology, University of Saskatchewan
Saskatoon

Sponsors and Collaborators

University of Saskatchewan

University of Regina

Investigators

Principal Investigator: Philip Chilibeck, Ph.D. University of Saskatchewan

Principal Investigator: Darren Candow, Ph.D. University of Regina

More Information
  • Responsible Party: University of Saskatchewan
  • ClinicalTrials.gov Identifier: NCT03941678 History of Changes
  • Other Study ID Numbers: 001
  • First Posted: May 8, 2019 Key Record Dates
  • Last Update Posted: June 11, 2020
  • Last Verified: June 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Stroke